Free Newsletter
Merck adds $300M, 180 jobs at NC plant
Color North Carolina pleased. Merck plans to invest an additional $300 million in a vaccine plant in Durham, expanding it beyond its original scope. The project is expected to yield up to 180 new jobs, bringing the total to be employed at the enormous facility to around 400.
With initial construction on the plant complete, builders are now working on a sterile processing facility, quality-testing labs, and high-speed packaging line. Another construction phase is set to begin next year. Though one processing line is up and running, it has yet to receive FDA approval. Once the facility is complete, it will supply childhood vaccines and a shingles shot for adults--and will account for some $700 million in capital expense on Merck's part. Yet more evidence that vaccines are among pharma's hottest products these days.
- read the CNBC brief
Related Articles:
Merck's McGlynn has key role developing vaccines
New tech drives huge growth in vaccine business
Vaccine "renaissance" attracts huge new venture investments
Novartis to build $600M flu plant in N.C.
Comments
merck is a good firm where a person can choose a luminative career.i want to job in this company
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





